SYTL3 and urinary bladder cancer: Six candidate variants identified, of which 2 have previously characterized tumorigenic roles: (a) Increased expression of SMOX is associated with gastric cancer, and (b) SYTL3 encodes proteins which interact with RAB27 and deregulation of this pathway is associated with bladder cancer.